Murata, S.; Oshima, N.; Iwasa, T.; Fukao, Y.; Sawata, M.
Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies 2023, 12, 22.
https://doi.org/10.3390/antib12010022
AMA Style
Murata S, Oshima N, Iwasa T, Fukao Y, Sawata M.
Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies. 2023; 12(1):22.
https://doi.org/10.3390/antib12010022
Chicago/Turabian Style
Murata, Shinya, Nobuyuki Oshima, Takashi Iwasa, Yukako Fukao, and Miyuki Sawata.
2023. "Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study" Antibodies 12, no. 1: 22.
https://doi.org/10.3390/antib12010022
APA Style
Murata, S., Oshima, N., Iwasa, T., Fukao, Y., & Sawata, M.
(2023). Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies, 12(1), 22.
https://doi.org/10.3390/antib12010022